*If prior authorization is not submitted, test may be delayed.
Polymerase chain reaction (PCR) with fragment analysis by capillary electrophoresis. Mutation confirmation by Sanger sequencing is performed on select cases.
CALR gene mutations occur at a frequency of 20-30% in primary myelofibrosis (PMF) and essential thrombocythemia (ET). Testing for CALR mutations can aid in the diagnosis of these myeloproliferative neoplasms. CALR mutations are typically exclusive of the JAK2 V617F mutation and are common (~50-75%) in PMF and ET cases that test negative for JAK2 V617F. The utilization of JAK2 V617F, CALR, and also MPL mutation testing provides detection of a clonal marker in the majority (>85%) of patients with PMF and ET. This CALR mutation test qualitatively detects all CALR exon 9 insertion and deletion mutations to a sensitivity of 2-5% mutant allele.
Interpretive report provided.
The limit of detection of this assay is 10% mutation-bearing cells. Mutations may not be detected in samples with a neoplastic burden below this level.
2 - 7 days
- Primary Myelofibrosis (PMF)
- Essential Thrombocythemia (ET)
Collect blood or bone marrow in a lavender top tube. Refrigerate and send intact blood or bone marrow specimen within 48 hours of collection. Fresh cell suspensions in RPMI should be refrigerated and sent, preferably within 48 hours. Frozen cell suspensions – preferably frozen with 1 hour of collection – may also be sent frozen on dry ice.
By ordering this test the clinician acknowledges that informed consent has been obtained from the patient as required by applicable state or federal laws and the ordering clinician has authorization from the patient permitting MLabs to report the test results to the ordering clinician. Test includes pathologist interpretation of results billed as a separate additional charge. This test is not available without interpretation.